Filing Details

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No.     )*

 

 

Akari Therapeutics, PLC

(Name of Issuer)

 

Ordinary Shares, par value £0.01 per share

(represented by American Depositary Shares)

(Title of Class of Securities)

 

00972G108

(CUSIP Number)

 

July 3, 2019

(Date of Event which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this schedule is filed:

 

☐ Rule 13d-1(b)

 

☒ Rule 13d-1(c)

 

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 00972G108

SCHEDULE 13G

Page 2 of 5

 

1		NAME OF REPORTING PERSON     Samir R. Patel
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP   (a)  ☐        (b)  ☐
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION     United States

NUMBER OF SHARES  BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5		SOLE VOTING POWER     1,475,523 shares(1)
		6		SHARED VOTING POWER     0 shares
		7		SOLE DISPOSITIVE POWER     1,475,523 shares(1)
		8		SHARED DISPOSITIVE POWER     0 shares

9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON     1,475,523 shares(1)
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)     7.1%
12		TYPE OF REPORTING PERSON     IN

 

(1)

Comprised of Ordinary Shares represented by American Depositary Shares. Each American Depositary Share reported represents 100 Ordinary Shares. Includes warrants to purchase up to 325,000 American Depositary Shares.

 

 

CUSIP No. 00972G108

SCHEDULE 13G

Page 3 of 5

 

Item 1(a).

Name of Issuer

 

Akari Therapeutics, PLC (the “Issuer”)

 

Item 1(b).

Address of Issuer’s Principal Executive Offices

 

75/76 Wimpole Street

 

London W1G 9RT

 

United Kingdom

 

Item 2(a).

Name of Person Filing

 

Samir R. Patel (the “Reporting Person”)

 

Item 2(b).

Address of Principal Business Office or, if None, Residence

 

The address of the principal business and principal office of the Reporting Person is:

 

1701 Chicon St., Austin, Texas, 78702

 

Item 2(c).

Citizenship

 

Samir R. Patel is a citizen of the United States.

 

Item 2(d).

Title of Class of Securities

 

Ordinary Shares, par value £0.01 per share (represented by American Depositary Shares, each of which represents 100 Ordinary Shares)

 

Item 2(e).

CUSIP Number

 

00972G108

 

Item 3.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

	(a)		☐		Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
	(b)		☐		Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)		☐		Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)		☐		Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
	(e)		☐		An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

 

 

CUSIP No. 00972G108

SCHEDULE 13G

Page 4 of 5

 

	(f)		☐		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
	(g)		☐		A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
	(h)		☐		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
	(i)		☐		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
	(j)		☐		Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

Item 4.

Ownership

 

With respect to the beneficial ownership of the Reporting Person, see Items 5 through 11 of the cover pages to this Schedule 13G, which are incorporated herein by reference.

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not Applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not Applicable.

 

Item 10.

Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

CUSIP No. 00972G108

SCHEDULE 13G

Page 5 of 5

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: October 4, 2019

 

	/s/ Samir R. Patel
	Samir R. Patel